Plain-English translation of NCT05614739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Urinary Bladder Neoplasms research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new drug called (also known as LY3866288) to treat advanced or metastatic urothelial cancer and other solid tumors with a specific genetic alteration in FGFR3. Researchers want to find the safest and most effective dose of this medication, and will also test whether combining it with other approved cancer treatments works better. The trial is enrolling up to 535 participants across multiple centers.
Many people with advanced bladder cancer need new treatment options that work better than current standard therapies. This medication is designed to target a specific genetic change (FGFR3) found in some bladder cancers, which may help the body fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you will take the medication by mouth (as a pill) daily, either alone or combined with intravenous infusions of other cancer drugs given at a clinic or hospital. The study involves multiple visits for blood work, imaging scans, and safety checkups. Early groups in the study will help doctors find the right dose; later groups will test how well the medication works at that dose. Your specific schedule and duration will depend on which phase and cohort you are assigned to.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States